Scarica l'app Stockscreener
6.3247
1.36%
0.0847
Precedente Chiudi:
$6.24
Aprire:
$6.2669
Volume 24 ore:
26,575
Relative Volume:
0.45
Capitalizzazione di mercato:
$140.47M
Reddito:
$56.13M
Utile/perdita netta:
$-14.67M
Rapporto P/E:
-8.5469
EPS:
-0.74
Flusso di cassa netto:
$-9.13M
1 W Prestazione:
+6.84%
1M Prestazione:
+25.24%
6M Prestazione:
+0.55%
1 anno Prestazione:
+84.93%
Intervallo 1D:
$6.00
$6.35
Intervallo di 1 settimana:
$5.64
$6.35
Portata 52W:
$3.2001
$6.8899
Journey Medical Corp Stock (DERM) Company Profile
Nome
Journey Medical Corp
Settore
Telefono
480-434-6670
Indirizzo
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Confronta DERM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
6.32 | 140.47M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
161.26 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.07 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.69 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | ROTH MKM | Buy |
| 2021-12-07 | Iniziato | B. Riley Securities | Buy |
Journey Medical Corp Borsa (DERM) Ultime notizie
Journey Medical Corp Appoints New Chief Operating Officer - TipRanks
Q1 EPS Estimates for Journey Medical Reduced by Roth Capital - MarketBeat
Journey Medical appoints new COO amid growth phase - Investing.com
Journey Medical Strengthens Leadership: New COO to Drive Emrosi Launch Strategy - Stock Titan
Journey Medical (NASDAQ:DERM) Issues Earnings Results - MarketBeat
Q3 EPS Estimates for Journey Medical Boosted by Roth Capital - MarketBeat
FY2027 EPS Estimate for Journey Medical Decreased by Analyst - Defense World
FY2027 EPS Estimates for Journey Medical Reduced by Analyst - MarketBeat
Roth Capital Lowers Earnings Estimates for Journey Medical - Defense World
Q3 EPS Estimates for Journey Medical Increased by Analyst - Defense World
Journey Medical Corporation (NASDAQ:DERM) Q4 2024 Earnings Call Transcript - Insider Monkey
Journey Medical Reports 2024 Financial Results - TipRanks
Journey Medical’s Earnings Call Highlights MROSI Launch and Growth Potential - TipRanks
Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ... By GuruFocus - Investing.com Canada
Journey Medical earnings beat by $0.27, revenue fell short of estimates - Investing.com
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss - Investing.com India
Earnings call transcript: Journey Medical’s Q4 2024 results highlight IMROCI launch - Investing.com
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates - Yahoo Finance
Journey Medical reports FY24 EPS (72c) vs (21c) last year - TipRanks
Journey Medical Corp reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance
New Study Compares Topical Serum and Pulse Light Therapy for Rosacea - Dermatology Times
Journey Medical launches Emrosi for the treatment of rosacea - Yahoo Finance
Power Up the Teyvat Journey: UGREEN Launches Genshin Impact Co-Branded Charging Collection - Yahoo Finance
23andMe's journey from DNA testing pioneer to bankruptcy - Yahoo Finance
Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea - Dermatology Times
Breakthrough: First Low-Dose Minocycline Treatment for Rosacea Shows Superior Results - Stock Titan
Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 20.5% - MarketBeat
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - Yahoo Finance
Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Claude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock - MarketBeat
Journey Medical (DERM) to Release Quarterly Earnings on Thursday - Defense World
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - The Manila Times
Journey Medical CEO Sets Stage for Major Updates at ROTH Conference - StockTitan
Journey Medical’s CEO sells $246,847 in stock By Investing.com - Investing.com South Africa
CEO Cashes Out: Major Stock Sale at Journey Medical Corp - TipRanks
Journey Medical’s CEO sells $246,847 in stock - Investing.com India
Journey Medical CEO Claude Maraoui sells shares worth $203,451 By Investing.com - Investing.com Canada
Journey Medical CEO Claude Maraoui sells shares worth $203,451 - Investing.com Australia
Journey Medical Co. (NASDAQ:DERM) CEO Sells $122,006.52 in Stock - MarketBeat
Claude Maraoui Sells 18,147 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula - PR Newswire
Journey Medical Corp Azioni (DERM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
7.85%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):